Papillary Thyroid Cancer

Surgical Oncology Clinics of North America

Volumn 15, Issue 3, 2006, Pages 585-601

  Sosa, Julie Ann ^a   Udelsman, Robert ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BORTEZOMIB; DOXORUBICIN; GELDANAMYCIN; IODINE 131; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN RET; RAS PROTEIN; THYROTROPIN;

BEAM THERAPY; BENIGN TUMOR; CALCIFICATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DOPPLER ECHOGRAPHY; GENE MUTATION; HUMAN; LABORATORY TEST; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; LYMPHADENOPATHY; MALIGNANT TRANSFORMATION; METASTASIS; PATHOLOGY; PROGNOSIS; RECURRENCE RISK; REVIEW; SUBTOTAL THYROIDECTOMY; THYROID PAPILLARY CARCINOMA; THYROID SURGERY; THYROIDECTOMY;

BIOPSY, FINE-NEEDLE; CALCINOSIS; CARCINOMA, PAPILLARY; COMBINED MODALITY THERAPY; HUMANS; IODINE RADIOISOTOPES; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 33746341206     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2006.05.010     Document Type: Review

References (40)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Sugitani I., Kasai N., Fujimoto Y., et al. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery 135 (2004) 139-148
3. Chow S.M., Law S.C.K., Chan J.K.C., et al. Papillary microcarcinoma of the thyroid - prognostic significance of lymph node metastases and multifocality. Cancer 98 (2003) 31-40
4. Hundahl S.A., Fleming I.D., Fremgen A.M., et al. A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer 83 (1998) 2638-2648
5. Russell W.O., Ibanez M.L., Clark R.L., et al. Thyroid carcinoma. Classification, intraglandular dissemination, and clinicopathological study based upon whole organ sections of 80 glands. Cancer 16 (1963) 1425
6. Rosai J. papillary carcinoma. Monogr Pathol 335 (1993) 138-165
7. Vickery A.L., Carcangiu M.L., Johannessen J.V., et al. Papillary carcinoma. Semin Diagn Pathol 2 (1985) 90
8. Bell C.D., Coire C., Treger T., et al. The "dark nucleus" and disruptions of the follicular architecture: possible new histological aids for the diagnosis of the follicular variant of papillary carcinoma of the thyroid. Histopathology 39 (2001) 33-42
9. Jun P., Chow L.C., and Jeffrey R.B. The sonographic features of papillary thyroid carcinomas. Ultrasound Q 21 (2005) 39-45
10. Papini E., Guglielmi R., Bianchini A., et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab 87 (2002) 1941-1946
11. Frates M.C., Benson C.B., Doubilet P.M., et al. Can color Doppler sonography aid in the prediction of malignancy of thyroid nodules?. J Ultrasound Med 22 (2003) 127-131
12. Chan B.K., Desser T.S., McDougall I.R., et al. Common and uncommon sonographic feature of papillary thyroid carcinoma. J Ultrasound Med 22 (2003) 1083-1090
13. Kessler A., Rappaport Y., Blank A., et al. Cystic appearance of cervical lymph nodes is characteristic of metastatic papillary thyroid carcinoma. J Clin Ultrasound 31 (2003) 21-25
14. Nelson R.L., Wahner H.W., and Gorman C.A. Rectilinear thyroid scanning as a predictor of malignancy. Ann Intern Med 88 (1978) 41-44
15. Cooper D.S., Doherty G.M., Haugen B.R., et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16 (2006) 109-142
16. Hay I., Grant C., Bergstralh E., et al. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma?. Surgery 124 6 (1998) 958-964 [discussion 964-6]
17. Hay I., Grant C., van Heerden J., et al. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery 112 6 (1992) 1139-1146 [discussion 1146-7]
18. Ito Y., Tomoda C., Uruno T., et al. Papillary microcarcinoma of the thyroid: how should it be treated?. World J Surg 28 11 (2004) 1115-1121
19. Pellegriti G., Scollo C., Lumera G., et al. Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases. J Clini Endocrinol Metab 89 (2004) 3713-3720
20. Beierwaltes W.H., Rabbani R., Dmuchowski C., et al. An analysis of "ablation of thyroid remnants" with I-131 in 511 patients from 1947-1984: experience at University of Michigan. J Nucl Med 25 12 (1984) 1287-1293
21. McGriff J., Csako G., Gourgiotis L., et al. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 34 (2002) 554-564
22. Eustatia-Rutten C., Smit J., Romijn J., et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf) 61 (2004) 61-74
23. Lima N., Cavaliere H., Tomimori E., et al. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer. J Endocrinol Invest 25 (2002) 110-115
24. Chiovato L., Latrofa F., Braverman L., et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 139 (2003) 346-351
25. Li D., Butt A., Clarke S., et al. Real-time quantitative PCR measurement of thyroglobulin mRNA in peripheral blood of thyroid cancer patients and healthy subjects. Ann N Y Acad Sci 1022 (2004) 147-151
26. Pacini F., Molinaro E., Castagna M., et al. Recombinant human TSH stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88 (2003) 3668-3673
27. Helal B., Merlet P., Toubert M., et al. Clinical impact of (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 42 (2001) 1464-1469
28. Haugen B. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 16 (1999) 34-41
29. Cady B., Sedgwick C.E., Meissner W.A., et al. Risk factor analysis in differentiated thyroid cancer. Cancer 43 (1979) 810
30. Cady B., and Rossi R.L. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 104 (1988) 947
31. Hay I.D., Grant C.S., Taylor W.F., et al. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 102 (1987) 1088
32. Hermaneck H., and Sobin L.H. TNM classification of malignant tumours: International Union Against Cancer. 4th edition (1987), Springer-Verlag, New York
33. Beahrs O.H., Henson D.E., Hutter R.V.P., et al. Manual for staging of cancer: American Joint Commission in Cancer. 3rd edition (1988), JB Lippincott, Philadelphia (PA)
34. Cancer Staging Manual AJCC. 6th edition (2002), Springer-Verlag, New York
35. Leboulleux S., Rubino C., Baudin E., et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 90 (2005) 5723-5729
36. Alberti L., Carniti C., Miranda C., et al. RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol 195 (2003) 168-186
37. Fagin J.A. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol 183 (2004) 249-256
38. Xing M., Westra W.H., Tufano R.P., et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90 (2005) 6373-6379
39. Vasko V., Hu S., Wu G., et al. High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab 90 (2005) 5265-5269
40. Guarino V., Faviana P., Salvatore G., et al. Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. J Clin Endocrinol Metab 90 (2005) 5270-5278